US FDA approves Bristol Myers' schizophrenia drug
Shares up about 4% in extended trading
FDA approval for new type of schizophrenia treatment
Bristol prices drug at $1,850 a month
Adds shares in paragraph 4, pricing details in paragraph 5 and company comments in paragraphs 10-11
By Bhanvi Satija and Michael Erman
Sept 26 (Reuters) -The U.S. FDA approved Bristol Myers Squibb's BMY.N schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects.
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last year. The drugmaker is banking on the treatment to help power growth as patents on its older cancer drug Revlimid and blood thinner Eliquis expire later this decade.
William Blair analysts expect $2.5 billion in U.S. sales for the drug by 2030. Bristol shares rose 4% in extended trading.
Bristol said it expects to make the drug available to patients by late October, at a list price of $1,850 a month or about $22,500 annually.
FDA's approval was based on data from two studies in which patients on the drug experienced a meaningful reduction in symptoms. The drug is the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care.
"So there is an unmet need still in the treatment of schizophrenia, particularly in patients who may show response to the positive symptoms but still have residual negative symptoms," said Alan Schatzberg, psychiatry professor at Stanford University School of Medicine.
Schatzberg said the drug could be a "game changer" for schizophrenia patients.
While antipsychotics that target dopamine receptors reduce symptoms of the disorder, their use also causes side effects such as tremors or involuntary movements and sleepiness.
Common side effects from Cobenfy in trials included vomiting, nausea, constipation among others. The FDA said Cobenfy should not be prescribed to patients with urinary retention, or those with moderate or severe kidney or liver disease.
Bristol expects 80% of the drug's patient population to be covered under Medicare and Medicaid insurance plans in the 12 to 18 months of its launch.
"Our focus is to ensure that all of these coverage decisions are made very quickly after launch, so we can have access for patients," said Chief Commercialization Officer Adam Lenkowsky.
The company expected to see significant utilization of the drug by the end of 2025, he added.
Currently approved antipsychotic drugs include Vanda Pharmaceuticals' VNDA.O Fanapt, AbbVie's ABBV.N Vraylar and generic drugs like olanzapine, quetiapine and aripiprazole, among others.
AbbVie is also developing newer drugs for the disease after its $8.7 billion takeover of Cerevel Therapeutics late last year. Reviva Pharmaceuticals RVPH.O, Neurocrine Biosciences NBIX.O and Celon Pharma CLNP.WA are also developing treatments for schizophrenia.
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Krishna Chandra Eluri and Alan Barona
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.
